4147.TWO Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 07:30):

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases...

Stats
Dagens volum	499 686
Gjennomsnittsvolum	2.40M
Markedsverdi	21.00B
EPS	TWD0 ( 2024-03-11 )
Neste inntjeningsdato	( TWD0 ) 2024-05-08
Last Dividend	TWD0 ( N/A )
Next Dividend	TWD0 ( N/A )
P/E	-109.21
ATR14	TWD0.0670 (0.08%)

Volum Korrelasjon

Lang: -0.07 (neutral)

Kort: -0.84 (strong negative)

Signal:(43.984) Neutral

TaiMed Biologics Inc. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

TaiMed Biologics Inc. Korrelasjon - Valuta/Råvare

0.43
( neutral )

0.51
( weak )

0.00
( neutral )

0.52
( weak )

0.31
( neutral )

-0.45
( neutral )

TaiMed Biologics Inc. Økonomi

Annual	2023
Omsetning:	TWD491.78M
Bruttogevinst:	TWD225.23M (45.80 %)
EPS:	TWD-0.760

FY	2023
Omsetning:	TWD491.78M
Bruttogevinst:	TWD225.23M (45.80 %)
EPS:	TWD-0.760

FY	2022
Omsetning:	TWD563.01M
Bruttogevinst:	TWD215.71M (38.31 %)
EPS:	TWD-1.090

FY	2021
Omsetning:	TWD413.44M
Bruttogevinst:	TWD83.96M (20.31 %)
EPS:	TWD-1.867

Financial Reports:

No articles found.

TaiMed Biologics Inc.

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases. The company develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-380, a neutralizing HIV-1 antibody. The company was incorporated in 2007 and is headquartered in Taipei, Taiwan.